These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Experimental study of ultralow-dose antibodies to cyclophosphamide on cyclophosphamide myelotoxicity.
    Author: Epstein OI, Dygai AM, Sergeeva SA, Zhdanov VV, Khrichkova TY, Stavrova LA, Zyuz'kov GN, Udut EV, Simanina EV.
    Journal: Bull Exp Biol Med; 2009 Mar; 147(3):323-7. PubMed ID: 19529853.
    Abstract:
    The possibility of using ultralow-dose cyclophosphamide for reducing the myelotoxicity of cyclophosphamide, injected in the maximum permissible dose, was studied in mice. Combined treatment by the cytostatic and its ultralow-dose preparation led to a lesser suppression of the erythroid, lymphocytic, and particularly granulocytic hemopoiesis stems. This effect is explained by stimulation of the secretory activity of hemopoiesis-inducing microenvironment and hence, of the functional activity of granulocytopoiesis under the effect of ultralow-dose cyclophosphamide.
    [Abstract] [Full Text] [Related] [New Search]